Live stream preview

Next video will start in 30 seconds

Serendipitous Beginnings for SGLT Inhibitors: A Cardiology Primer

Close Open

Hypertrophic Cardiomyopathy: Decoding the Mystery of a Thickened Heart

The Point Podcast • 34m

Up Next in The Point Podcast

  • Serendipitous Beginnings for SGLT Inh...

    The Texas Heart Institute’s Drs. Salim Virani and Matthew Segar look back at the history of Sglt2 inhibitors, which have roots in a fascinating FDA initiative focused on cardiovascular outcomes in diabetes medications. They explore the serendipitous beginnings of these groundbreaking medicines an...